DISEASE INDICATIONS: Skin Cancer
MANUFACTURER: Sun Pharmaceutical Industries Europe B.V.
USAGE: Oral
MEDICINE APPROVED BY:
European Medical Agency (EMA)
Food and Drug Administration (FDA)
Therapeutic Goods Administration (TGA)
Odomzo, also known by its generic name Sonidegib, is a remarkable medication that has ushered in new hope for individuals grappling with the challenges of Advanced Basal Cell Carcinoma (BCC), a type of skin cancer that can be both disfiguring and debilitating.
